These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 31223261

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
    Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ.
    World J Gastroenterol; 2013 Jan 21; 19(3):339-46. PubMed ID: 23372355
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H, Li B, Li Z, Wei Q, Ren L.
    BMC Cancer; 2021 Apr 13; 21(1):401. PubMed ID: 33849479
    [Abstract] [Full Text] [Related]

  • 8. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000.
    Ryu MR, Kang ES, Park HD.
    J Clin Lab Anal; 2019 Jul 13; 33(6):e22921. PubMed ID: 31131509
    [Abstract] [Full Text] [Related]

  • 9. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma.
    Qi F, Zhou A, Yan L, Yuan X, Wang D, Chang R, Zhang Y, Shi F, Han X, Hou J, Wei L, Zhang X.
    J Clin Lab Anal; 2020 May 13; 34(5):e23158. PubMed ID: 31821607
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH.
    Scand J Gastroenterol; 2016 Mar 13; 51(3):344-53. PubMed ID: 26340708
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
    Svobodova S, Karlikova M, Topolcan O, Pecen L, Pestova M, Kott O, Treska V, Slouka D, Kucera R.
    In Vivo; 2018 Mar 13; 32(6):1551-1554. PubMed ID: 30348715
    [Abstract] [Full Text] [Related]

  • 15. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
    Ji J, Liu L, Jiang F, Wen X, Zhang Y, Li S, Lou J, Wang Y, Liu N, Guo Q, Jia Y, Gao C.
    J Clin Lab Anal; 2021 Nov 13; 35(11):e24013. PubMed ID: 34590755
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S, Jiang F, Wang Y, Yu Y, Ren S, Wang X, Yin P, Lou J.
    Tumour Biol; 2017 Jun 13; 39(6):1010428317705763. PubMed ID: 28621228
    [Abstract] [Full Text] [Related]

  • 18. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ, Han KH, Kim DY.
    Scand J Gastroenterol; 2009 Jun 13; 44(7):861-6. PubMed ID: 19391065
    [Abstract] [Full Text] [Related]

  • 19. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
    Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P.
    Aliment Pharmacol Ther; 2022 Feb 13; 55(3):350-359. PubMed ID: 34738664
    [Abstract] [Full Text] [Related]

  • 20. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
    Qin X, Tang G, Gao R, Guo Z, Liu Z, Yu S, Chen M, Tao Z, Li S, Liu M, Wang L, Hou L, Xia L, Cheng X, Han J, Qiu L.
    Int J Lab Hematol; 2017 Aug 13; 39(4):392-401. PubMed ID: 28318145
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.